VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of VYXEOS (daunorubicin and cytarabine) liposome brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the VYXEOS (daunorubicin and cytarabine) liposome medicine cost price in India.
The order for VYXEOS (daunorubicin and cytarabine) liposome will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Daunorubicin and cytarabine (liposomal) is the generic name for the trade name drug Vyxeos™. Daunorubicin and Cytarabine Liposome (Vyxeos™) is a combination of two medications, daunorubicin, an anthracycline, and cytarabine, an antimetabolite. Anthracyclines work by interrupting the copying of DNA, which is necessary for cancer cell growth. This causes the cancer cells to die, slowing or stopping tumor growth. Antimetabolites interfere with DNA production. This stops cell growth and division, resulting in the slowing or stopping of cancer growth. Since cancer cells, in general, divide faster and with less error-correcting than healthy cells, cancer cells are more sensitive to this damage. This combination of these two medications has been shown to kill leukemia cells better than when the medications are given separately.
VYXEOS™ (daunorubicin and cytarabine) liposome for injection, for intravenous use Initial U.S. Approval: 2017
Generic Name: daunorubicin and cytarabine
For injection: 44 mg daunorubicin and 100 mg cytarabine encapsulated in liposomes as a lyophilized cake in a single-dose vial for reconstitution.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand VYXEOS (daunorubicin and cytarabine) liposome on prescription and Import License in Patient's Name only.
For overseas patients, VYXEOS (daunorubicin and cytarabine) liposome can be made available in Send your enquiry to find VYXEOS (daunorubicin and cytarabine) liposome in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For VYXEOS™ (daunorubicin and cytarabine) liposome Injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia For More Details
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea For More Details